Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Tremelimumab in Chinese Patients with Advanced Malignancies
NCT02978482Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2016
- Primary completion
- Jan 2018
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label trial of durvalumab and tremelimumab in solid tumor (advanced stage) and nasopharyngeal carcinoma (NPC) (2 arms), sponsored by AstraZeneca. Primary endpoints: Maximum plasma concentration at 6 months, Trough plasma concentration at 6 months and 3 more. Started Dec 2016; status: completed.
02
Drugs
durvalumabtremelimumab
03
Conditions
solid tumor (advanced stage)nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT02978482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02978482.